"Licensing the development and distribution of Phytofare™ products for the nutraceutical industry to Phyto Nutricare allows Plandai to focus on the development of new extractions and the pursuit of pharmaceutical drug targets," Mr. Duffield added.
Phyto Nutricare further cemented this relationship by appointing Callum Baylis-Duffield as its President and Chief Executive Officer. Mr. Baylis-Duffield serves on the Board of Directors of Plandai and holds the position of Vice President of Sales and Marketing. He is a graduate in International Business with French (BA Hons) from the University of the West of England. From 2007-2010, he was employed by Johnson and Johnson UK as a marketing & sales manager of a proprietary surgical device. Mr. Baylis-Duffield has been involved with the research and development of the Plandai's proprietary emulsions since 2004 and has worked extensively with the USA scientific team.
Mr. Baylis-Duffield commented, "I'm excited to be back in the UK to head up the introduction of Phytofare™ extracts to the nutraceutical market. Our immediate objective is to complete the final product profiling and testing and then formalize our sales and distribution channels so that we are positioned for maximum market penetration once the first product is available. My job is made easier by having extracts that have greater purity, superior anti-oxidant properties and unmatched bioavailability."
Plandai expects to shortly commence a human clinical trial to targeting bioavailability, obesity, high cholesterol, hypertension and high blood pressure, with results expected in late Q3.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. and its subsidiaries, focus on the farming of whole fruits, vegetables and live plant material
|SOURCE Plandai Biotechnology, Inc.|
Copyright©2012 PR Newswire.
All rights reserved